New York Life Investment Management LLC Makes New Investment in Revvity, Inc. (NYSE:RVTY)

New York Life Investment Management LLC purchased a new position in shares of Revvity, Inc. (NYSE:RVTY) in the 4th quarter, Holdings Channel.com reports. The firm purchased 17,361 shares of the company’s stock, valued at approximately $1,898,000.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of RVTY. Parkside Financial Bank & Trust purchased a new stake in shares of Revvity in the fourth quarter valued at about $25,000. Gladius Capital Management LP increased its position in Revvity by 84.1% during the 3rd quarter. Gladius Capital Management LP now owns 232 shares of the company’s stock worth $26,000 after purchasing an additional 106 shares during the period. CENTRAL TRUST Co purchased a new stake in shares of Revvity in the fourth quarter valued at approximately $27,000. ORG Partners LLC purchased a new position in Revvity in the fourth quarter worth $32,000. Finally, JTC Employer Solutions Trustee Ltd purchased a new stake in shares of Revvity during the 4th quarter worth $33,000. 86.65% of the stock is currently owned by hedge funds and other institutional investors.

Revvity Stock Performance

Shares of NYSE RVTY opened at $102.82 on Tuesday. The company has a 50-day simple moving average of $104.53 and a 200-day simple moving average of $101.26. The company has a debt-to-equity ratio of 0.40, a current ratio of 2.23 and a quick ratio of 1.92. The company has a market cap of $12.70 billion, a PE ratio of 84.98, a price-to-earnings-growth ratio of 2.62 and a beta of 1.09. Revvity, Inc. has a 12 month low of $79.50 and a 12 month high of $131.96.

Revvity (NYSE:RVTY) last released its earnings results on Monday, April 29th. The company reported $0.98 EPS for the quarter, topping the consensus estimate of $0.94 by $0.04. Revvity had a net margin of 5.49% and a return on equity of 7.37%. The firm had revenue of $649.90 million during the quarter, compared to analysts’ expectations of $646.83 million. During the same period in the previous year, the company earned $1.01 EPS. Revvity’s revenue for the quarter was down 3.7% on a year-over-year basis. On average, equities analysts anticipate that Revvity, Inc. will post 4.66 earnings per share for the current year.

Revvity Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, August 9th. Shareholders of record on Friday, July 19th will be issued a $0.07 dividend. This represents a $0.28 annualized dividend and a yield of 0.27%. The ex-dividend date of this dividend is Friday, July 19th. Revvity’s dividend payout ratio (DPR) is 23.14%.

Analyst Ratings Changes

A number of research firms recently commented on RVTY. Robert W. Baird boosted their price objective on shares of Revvity from $126.00 to $127.00 and gave the stock an “outperform” rating in a report on Tuesday, April 30th. Barclays boosted their price target on Revvity from $92.00 to $105.00 and gave the stock an “equal weight” rating in a research note on Thursday, January 25th. KeyCorp raised their price objective on Revvity from $110.00 to $126.00 and gave the company an “overweight” rating in a research note on Friday, February 2nd. TD Cowen boosted their target price on Revvity from $123.00 to $130.00 and gave the stock a “buy” rating in a research report on Tuesday, April 30th. Finally, Stifel Nicolaus raised their price target on Revvity from $95.00 to $110.00 and gave the company a “hold” rating in a research report on Friday, February 2nd. Six equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. According to data from MarketBeat, Revvity currently has an average rating of “Moderate Buy” and a consensus price target of $118.17.

Revvity Profile

Revvity, Inc provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market.